Check-Cap (NASDAQ:CHEK) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued on Wednesday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Trading Down 0.7 %

NASDAQ CHEK opened at $1.48 on Wednesday. The company has a market cap of $8.66 million, a P/E ratio of -0.49 and a beta of 0.36. The company has a fifty day simple moving average of $1.69 and a 200 day simple moving average of $2.01. Check-Cap has a 12-month low of $1.13 and a 12-month high of $3.94.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.